Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7793.018 | uM | inf | inf | 0.9318 | 0.9318 | 0.0000 | 0.0067 | 0.3477 | 1.3186 | |
| BT-20 | TNBC | Basal A | Pertuzumab | 5903.102 | mg/ml | inf | inf | 0.9324 | 0.9324 | 0.0000 | -0.0074 | -0.0405 | 1.2557 | |||
| 21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
| 21MT-1 | HER2amp | - | MG-132 | Proteasome | Proteasome | 14191.189 | uM | inf | inf | -0.1161 | -0.1161 | 0.0000 | 0.5482 | 0.5418 | 2.9704 | |
| 184A1 | NM | Basal | (Z)-4-Hydroxytamoxifen | ESR1 | 9047.132 | uM | inf | inf | 0.4055 | 0.4055 | 0.0000 | 0.2074 | 0.3073 | 0.6985 | ||
| AU565 | HER2amp | Luminal | Cisplatin | DNA cross-linker | DNA cross-linker | 9146.049 | uM | inf | inf | 0.5485 | 0.5485 | 0.0000 | 0.3293 | 0.0796 | 1.1054 | |
| BT-474 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 12056.155 | uM | inf | inf | 0.6967 | 0.6967 | 0.0000 | 0.1421 | 0.3782 | 0.8251 | |
| 21MT-1 | HER2amp | - | Ribavirin | 15382.211 | uM | inf | inf | 0.9683 | 0.9683 | 0.0000 | 0.0416 | 0.0000 | 1.1714 | |||
| BT-20 | TNBC | Basal A | Ro 32-0432 | PKC | PKC | 10581.142 | uM | inf | inf | 1.0451 | 1.0451 | 0.0000 | 0.0021 | -0.0023 | 0.7885 | |
| BT-474 | HER2amp | Luminal | SB-3CT | MMP2/9 | MMP | 12056.144 | uM | inf | inf | 0.7102 | 0.7102 | 0.0000 | 0.1537 | 0.4982 | 0.9738 | |
| BT-20 | TNBC | Basal A | Lapatinib | EGFR/HER2 | ErbB | 5904.098 | uM | inf | inf | 0.8819 | 0.8819 | 0.0000 | 0.0368 | 0.3491 | 1.3264 | |
| BT-20 | TNBC | Basal A | PD184352 | MEK | MAPK | 11854.155 | uM | inf | inf | 0.7890 | 0.7890 | 0.0000 | 0.0854 | -0.0152 | 1.3396 | |
| BT-474 | HER2amp | Luminal | Glycyl-H-1152 | ROCK2 | 12178.16 | uM | inf | inf | 0.7508 | 0.7508 | 0.0000 | 0.1609 | 0.0357 | 0.7392 | ||
| 600MPE | HR+ | Luminal | SB-3CT | MMP2/9 | MMP | 12224.144 | uM | inf | inf | 0.8442 | 0.8442 | 0.0000 | 0.1370 | -0.1637 | 1.0210 | |
| 600MPE | HR+ | Luminal | Dactolisib | PI3K | PI3K | 12224.155 | uM | inf | inf | 0.7744 | 0.7744 | 0.0000 | 0.1982 | 0.2284 | 1.0378 | |
| 600MPE | HR+ | Luminal | GW-5074 | CRAF | MAPK | 5898.088 | uM | inf | inf | 0.8157 | 0.8157 | 0.0000 | 0.0414 | -0.0040 | 0.6095 | |
| BT-474 | HER2amp | Luminal | 2-deoxyglucose | 13125.177 | uM | inf | inf | -0.1564 | -0.1564 | 0.0000 | 0.4335 | 0.4985 | 0.8991 | |||
| AU565 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 5900.065 | uM | inf | inf | 0.9321 | 0.9321 | 0.0000 | -0.0050 | 0.3225 | 2.2026 | |
| BT-20 | TNBC | Basal A | PS-1145 | IKK | NFKB | 5902.065 | uM | inf | inf | 0.7265 | 0.7265 | 0.0000 | 0.1074 | 0.4823 | 1.2690 | |
| 600MPE | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 12224.154 | uM | inf | inf | 0.7982 | 0.7982 | 0.0000 | 0.0654 | 0.1825 | 0.9590 | |
| 184A1 | NM | Basal | Cetuximab | EGFR | ErbB | 7787.018 | uM | inf | inf | 0.4652 | 0.4652 | 0.0000 | 0.3838 | -0.0013 | 0.3791 | |
| 600MPE | HR+ | Luminal | Cetuximab | EGFR | ErbB | 9118.006 | uM | inf | inf | 0.8545 | 0.8545 | 0.0000 | 0.0747 | 0.3005 | 1.1089 | |
| 21NT | HER2amp | - | Ribavirin | 15383.211 | uM | inf | inf | 1.0074 | 1.0074 | 0.0000 | 0.0469 | 0.0000 | 1.0341 | |||
| HBL-100 | Unknown | Unknown | Cetuximab | EGFR | ErbB | 7807.042 | uM | inf | inf | 1.0098 | 1.0098 | 0.0000 | -0.0392 | -7.7987 | 2.0250 | |
| HBL-100 | Unknown | Unknown | AG1478 | EGFR | ErbB | 7807.016 | uM | inf | inf | 0.9359 | 0.9359 | 0.0000 | 0.0541 | 0.4439 | 2.1516 |